Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma

The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC acr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2021-04, Vol.27 (7), p.1827-1829
Main Authors: Castet, Florian, Willoughby, Catherine E, Haber, Philipp K, Llovet, Josep M
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Humans
Liver Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages. .
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-20-4706